FDA claims it "unlikely" that Vytorin and Zetia increase cancer risk
This article was originally published in Scrip
Executive Summary
The US FDA says that Merck & Co's hypolipaemics Vytorin (ezetimibe plus simvastatin) and Zetia (ezetimibe) do not appear to be associated with an increased risk of cancer or cancer-related death compared with placebo following a review.